

IRF-1 siRNA (m): sc-35707

BACKGROUND

Interferon regulatory factor-1 (IRF-1) and IRF-2 have been identified as novel DNA-binding factors that function as regulators of both type I interferon (interferon- α and β) and interferon-inducible genes. The two factors are structurally related, particularly in their N-terminal regions, which confer DNA binding specificity. In addition, both bind to the same sequence within the promoters of interferon- α and interferon- β genes. IRF-1 functions as an activator of interferon transcription, while IRF-2 binds to the same *cis* elements and represses IRF-1 action. IRF-1 and IRF-2 have been reported to act in a mutually antagonistic manner in regulating cell growth; overexpression of the repressor IRF-2 leads to cell transformation while concomitant overexpression of IRF-1 causes reversion. IRF-1 and IRF-2 are members of a larger family of DNA binding proteins that includes IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, ISGF-3 γ p48 (a component of the ISGF-3 complex) and IFN consensus sequence-binding protein (ICSBP).

REFERENCES

1. Fujita, T., et al. 1988. Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN- β gene regulatory elements. *EMBO J.* 7: 3397-3405.
2. Harada, H., et al. 1989. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. *Cell* 58: 729-739.

CHROMOSOMAL LOCATION

Genetic locus: Irf1 (mouse) mapping to 11 B1.3.

PRODUCT

IRF-1 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see IRF-1 shRNA Plasmid (m): sc-35707-SH and IRF-1 shRNA (m) Lentiviral Particles: sc-35707-V as alternate gene silencing products.

For independent verification of IRF-1 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-35707A, sc-35707B and sc-35707C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

IRF-1 siRNA (m) is recommended for the inhibition of IRF-1 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

IRF-1 (E-4): sc-514544 is recommended as a control antibody for monitoring of IRF-1 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor IRF-1 gene expression knockdown using RT-PCR Primer: IRF-1 (m)-PR: sc-35707-PR (20 μ l, 518 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

SELECT PRODUCT CITATIONS

1. Kar, S., et al. 2009. Signaling events leading to the curative effect of cystatin on experimental visceral leishmaniasis: involvement of ERK1/2, NF κ B and JAK/STAT pathways. *Eur. J. Immunol.* 39: 741-751.
2. Lu, C., et al. 2016. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. *Oncoimmunology* 5: e1247135.
3. Luthra, P., et al. 2018. Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. *Antiviral Res.* 158: 288-302.
4. Ghosh, S., et al. 2018. TNF α mediated ceramide generation triggers cisplatin induced apoptosis in B16F10 melanoma in a PKC δ independent manner. *Oncotarget* 9: 37627-37646.
5. Gao, T., et al. 2019. Transcriptional regulation of homeostatic and disease-associated-microglial genes by IRF1, LXR β , and CEBP α . *Glia* 67: 1958-1975.
6. Sun, Y., et al. 2020. Increased AT $_2$ R expression is induced by AT $_1$ R autoantibody via two axes, Klf-5/IRF-1 and circErbB4/miR-29a-5p, to promote VSMC migration. *Cell Death Dis.* 11: 432.
7. Yan, Y., et al. 2021. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). *Cancer Lett.* 506: 95-106.

RESEARCH USE

For research use only, not for use in diagnostic procedures.